OpportunityTitle: Limited Competition: Continuation of the Preventing Early Renal Loss in Diabetes (PERL) Study (UC4)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are  allowed.  This FOA is a limited competition for the continuation of the PERL study, which was previously funded under RFA-DK-12-511. Only the currently funded Clinical Research Center (CRC) is eligible to apply. Only the currently funded Biostatistics Research Center (BRC) and clinical sites are eligible to be subcontracts to the CRC.  see FOA for Eligibility Details
Description: The purpose of this Funding Opportunity Announcement (FOA) is to complete treatment of the participants recruited into the Preventing Early Renal Loss in Diabetes (PERL) Study and to analyze the outcomes of the trial. PERL is a randomized, double-blind trial to test whether the medication, allopurinol, can slow the progression of kidney disease in people with type 1 diabetes and early diabetic kidney disease.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;